A British startup has launched a self-contained chemical experiment into space, marking a new phase in longevity research. The experiment, developed by Mass Balance, is designed to study the behavior of disease-causing proteins in microgravity, potentially offering insights into age-related conditions like Alzheimer’s and Parkinson’s. The apparatus, which contains chemicals, sensors, and control elements, was deployed in a 10-centimeter pod built by Austrian company Tumbleweed and launched on a SpaceX transporter. The mission aims to collect data on how live cells function under weak gravity, which could lead to more accurate models for drug development.
The experiment is part of a broader effort to create a reliable research environment in space, according to Mass Balance co-founder and CEO Toby Call. He explained that removing gravity allows for unique observations that are difficult to achieve on Earth, where convection and sedimentation complicate data collection. Call emphasized that the goal is to make space a standard, reliable setting for scientific research, which could eventually help in imaging disordered proteins responsible for various diseases. These proteins are challenging to study on Earth due to their constant shape changes, which hinder the training of models like Google’s AlphaFold.
Mass Balance is currently focused on testing its platform’s operational system and data capture capabilities. The current mission involves sending an industrial biocatalyst into space to break down a chemical compound, with the platform monitoring the process using light. The startup is not planning to return the system to Earth, which reduces engineering challenges related to re-entry. Other biotech firms are also exploring space-based labs, but Mass Balance’s approach highlights a different focus on utilizing microgravity as a new research tool.
Source: wired
